More COVID-19 vaccine choice.
That was the outcome after the Food and Drug Administration moved to approve Novavax shots for adults in the U.S.
It’s already available in other countries across the world.
However, the move comes as nearly a quarter of all adults in the U.S. have not gotten their primary vaccination against COVID-19.
The Maryland company hopes that it can be a leader in booster shot choice, and serve that 25% gap in primary vaccination against the virus.
“I encourage anyone who is eligible for, but has not yet received, a COVID-19 vaccine to consider doing so,” FDA Commissioner Dr. Robert Califf said in a statement.
The vaccine is expected to get booster clearance in the coming weeks.